Omeros: Yartemlea Sales Slow, Pipeline Delays Test Cash Runway

Yartemlea (narsoplimab) is the only approved product at Omeros (OMER). The drug treats TA-TMA, a complication of stem cell transplants. Sales have climbed since launch. Growth is slowing.

A recent analysis on Seeking Alpha modeled the asset. Revenue gains are coming in below earlier expectations. The analyst flagged that pipeline projects keep getting pushed further out. Omeros is testing narsoplimab in other complement-mediated diseases. Phase 3 data has been delayed. No new readout date has been set.

Cash burn is the immediate concern. Omeros has no other revenue stream. Quarterly operating costs run well above Yartemlea's contribution. The balance sheet shows enough cash for roughly 12 months at the current burn rate, based on the last filing.

The stock trades at a discount to the analyst's net present value estimate. That NPV depends heavily on pipeline success. A failed trial would cut the valuation by more than half.

What would reduce the risk: positive phase 3 data in another indication or a licensing deal that brings non-dilutive funding. A faster-than-expected sales ramp in TA-TMA would also help. None of those are in hand.

What would worsen the outlook: another pipeline delay, weak prescription trends, or a secondary offering that dilutes existing shareholders.

The next scheduled catalyst is the year-end pipeline update. Omeros typically provides a review in December.